Higher serum activin A predicts adverse outcomes in AI-refractory hormone receptor-positive metastatic breast cancer in the Phase III BOLERO-2 trial (everolimus + exemestane vs exemestane alone)

Read full text Summarise with VIRAT
Authors: Laura K. Krecko, Ayesha Ali, Meghan M. Hupp, Ashley Kang, Hyma Vani Polimera, Suhail M. Ali, Kim Leitzel, Eric I Marks, Albert Reisling, Scott J. Hofsess, Robert Sweetman, Steve Nowmos
+12 more Daniel Rooks, Cristina I. Truica, Monali K. Vasekar, Vinod Nagabhairu, Angelique Ellerbee Richardson, Ashok Maddukuri, Prashanth Reddy Moku, Karen Muindi, Maren May, Gabriel N. Hortobágyi, Jose M Baselga, A. Lipton
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Fields of Study & Subjects

Advanced Breast Cancer Therapies Breast Cancer Treatment Studies PI3K/AKT/mTOR signaling in cancer

Publication details

Journal / source
SSRN Electronic Journal
Publication date
1 January 2026
Language
EN
Document type
Preprint